Wall Street Journal: Ovation in the News

“Researchers increasingly will use sequencing to discover treatments for complex conditions such as autoimmune, metabolic and neurological diseases, ” explained Barry Wark, Ovation’s Co-founder and Chief Strategy Officer.

Ovation’s Curt Medeiros joined Barry for an interview with The Wall Street Journal about the potential to improve precision medicine by increasing access to genomic data and why low-cost sequencing will help us get there.

Read the article and learn more about advances in genomic sequencing.

Get the latest news and updates about Ovation's Genomic Data offerings delivered to your inbox.

Linking Genomic and Phenotypic Data to Better Understand the Patient Journey

In partnership with Datavant, we explore how researchers can overcome the challenges posed by..

Case Study: Realizing the value of biospecimens for life sciences research in IBD


We looking forward to speaking with you!